ArticleOpen veterinary journal2025
Pharmacokinetic evaluation of a long-acting, tasteless oral formulation of enrofloxacin in dogs.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Owner medication compliance with the clinician's prescription can influence the patient's outcome, among other factors. Extending the dosing interval (DI) may improve medication compliance. Therefore, an oral long-acting (LA) preparation of enrofloxacin as minispheres was developed. Aim: To develop a tasteless LA preparation of enrofloxacin as minispheres that can achieve Cmax and AUC values equal to or greater than those of the reference flavored tablet. Additionally, the dose was concealed in either pate or cream cheese morsels to facilitate dosing of the experimental minispheres. Methods: The pharmacokinetics (PK) of the reference preparation and the experimental minispheres were defined by dosing them as two 10 mg/kg/day or 15 mg/kg once, respectively. The HCl·2H Results: The Cmax and AUC Conclusion: Given the PK/PD relationships obtained with the experimental minispheres, a 15 mg/kg dose every 48 hours (15 mg/kg) is recommended. This prototype will be presented to the veterinary clinical community for further evaluation to assess clinical efficacy and medication compliance performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.